FAKTOR-OPTIONSSCHEIN - MODERNA | Market Closed - Boerse Frankfurt Warrants 15:45:34 2024-06-25 EDT | ||
| 2.53 EUR | 0.00% |
|
| Current month | +7.66% | ||
| 1 month | +42.13% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-25 | 2.53 | 0.00% |
| 24-06-24 | 2.53 | -3.80% |
| 24-06-21 | 2.63 | -0.75% |
| 24-06-20 | 2.65 | -2.93% |
| 24-06-19 | 2.73 | +3.41% |
Real-time Boerse Frankfurt Warrants
Last update June 25, 2024 at 03:45 pm
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SF3GXU |
| ISIN | DE000SF3GXU3 |
| Date issued | 2021-08-12 |
| Strike | 456 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.07 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 30 € |
|---|---|
| Lowest since issue | 1.74 € |
| Spread | 0.02 € |
| Spread % | 0.79% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
137.6
USD
Average target price
145.9
USD
Spread / Average Target
+6.00%
- Stock Market
- Certificates
- Certificat
